The importance of the effects of ACE inhibitors on sudden death, progressive heart failure and recurrent infarction to the reduction in overall mortality in heart failure and after myocardial infarction is disputed.
Introduction
Recent large trials show that ACE inhibitors reduce mortality in patients with heart failure[l-JJ requiring deaths. Ramipril reduced the risk of sudden death by 30% (95% CI; 8-47%; P=O·Oll). However, overall, 45% of those patients who died suddenly had severe or worsening heart failure prior to their death. Only 39% of sudden deaths were considered to be due to arrhythmias. Ramipril reduced the risk of death from circulatory failure by 18%, but this did not reach statistical significance (95% CI; 41 to -14%; P=0·237). The magnitude of the effects on sudden death and death due to circulatory failure were not significantly different. However, 38% of the reduction in overall mortality was from the subgroup with sudden death who had developed prior severe resistant heart failure (placebo n=35, ramipril n= 15), again emphasizing the marked benefit in preventing failure. Ramipril did not selectively alter the proportion of in-to out-of-hospital deaths.
Table 1 Definitions used in validation of the secondary outcome
Severe/resistant heart failure was defined as:
e Clinical judgement of severe heart failure (usually NYHA grade IV) that is unresponsive to non-ACE-inhibitor treatment. Onset is usually the date on which open-label ACE-inhibitor treatment started. Reinfarction was defined as:
e Evolving diagnostic ECG, as defined by progressive changes in the ST segment and T-wave compatible with acute MI, with or without the presence of a pathological Q wave and prolonged cardiac pain.
e Evolving diagnostic ECG (as defined above) and/or abnormal enzymes (>2 x upper limit of the reference range.
e Prolonged cardiac pain and/or abnormal enzymes (>2 x upper limit of reference range).
Stroke was defined as:
e Rapid onset of localizing neurologic deficit and/or change in level or consciousness and e Documentation of localizing neurologic deficit with a duration >24 h and No other disease process or event such as brain tumour, subdural haematoma, subarachnoid haemorrhage, metabolic disorder, or peripheral lesion that could cause localizing neurologic deficit or coma. ventricular dilatation. In contrast, the V-HeFT-II study[ 2 l attributed the entire benefit of ACE inhibition to a reduction in sudden death, albeit frequently in the setting of worsening heart failure. The SAVE and TRACE studies suggest that reducing progressive heart failure and sudden death are both important[ 4 • 6 l. Whether ACE inhibitors reduce the risk of myocardial infarction remains controversial [ 2 ,6-9 l.
The· AIRE study[ 9 l randomized 2006 patients who exhibited some clinical or radiological feature of heart failure within 2-9 days of a myocardial infarction to placebo or ramipril 5 mg b.d. The primary end-point was all-cause mortality; the relative risk of death fell by 27% among those randomized to ramipril (P=0·002). The secondary end-point was the time to the first validated outcome, i.e. time to death or myocardial reinfarction, severe resistant heart failure or stroke. A tertiary pre-defined analysis was the mode of death[IOJ. The components of the secondary and tertiary outcomes are the subjects of this report.
The definition of sudden death has long been controversial and is more complex in patients with heart failure as death is an expected feature of the diagnosisP0l. Defining death due to heart failure is also problematic as few studies have prospectively defined what this constitutes[ 11 l. It is also apparent that the classification of the mode of death is highly subjectiveP2l. Most of the large studies have had end-points' committees in order to attain a greater uniformity in classification. Unfortunately, opinions will vary from one committee to another and clearer definition of outcomes are required [ 11 · 12 l . In contrast, the place where patients die is an informative and highly objective variable by which to classify death[ 11 l, but has not been reported previously for any major study of heart failure.
In the AIRE study death was classified, in an attempt to describe more accurately how patients die and how ACE inhibitors improve outcome, as follows[11l: (a) activity or place of death (e.g. exertion, inor out-of-hospital); (b) cause of death (e.g. myocardial rupture, ventricular arrhythmia etc.); (c) mode of death Eur Heart J, Vol. 18, January 1997 (e.g. sudden, circulatory etc.); (d) events associated with death (e.g. worsening heart failure, recent infarction).
In this way it was hoped that more tangible information on how patients with post-infarction heart failure died would be obtained. End-point definitions were formulated and submitted for publication prior to the randomization code of the study being broken and prior to data analysis.
Methods
The design and characteristics of patients randomized in the AIRE study have been described previously[ 9 • 10 l. The definitions used to validate outcomes contributing to the secondary outcome are shown in Table 1 . The Classification of the mode of death is shown in Table 2 . In addition detailed information on symptoms, time, place and activity prior to death was requested.
The process for reviewing and validating secondary and tertiary outcomes are described in detail elsewhere[10l. All outcomes were assessed independently by two members of the end-points committee from separate participating countries. Only after an independent opinion had been recorded was discussion permitted in order to reach agreement on validation.
The interpretation of the term severe resistant heart failure needs clarification. The term 'resistant' refers to resistance to treatment without ACE inhibitors. The AIRE study protocol was written when only data from the first CONSENSUS study was available to guide the use of ACE inhibitors. During the course of the AIRE study it became apparent, from other trials, that ACE inhibitors could reduce mortality in patients with less severe degrees of heart failure. Severe resistant heart failure was validated by the end-points committee over a short space of time at the end of the study before the study was unblinded. The term severe resistant heart failure was interpreted to mean worsening heart failure and that some non-ACE-inhibitor treatment for heart failure, usually in the form of a diuretic, had been tried. e Non-cardiovascular This included any death clearly due to a non-cardiovascular cause.
End-points contributing to the secondary outcome, such as the presence of severe resistant heart failure, and tertiary outcomes were validated by the end-points committee, but the judgement of whether a patient had worsening heart failure or not prior to death was according to the investigator's report. Thus a patient could be reported as having worsening heart failure but judged not to have severe resistant heart failure. Conversely, a patient could be judged to have severe resistant heart failure but be stable and therefore not have worsening heart failure, while other patients could have both. Worsening heart failure was further categorized into those patients who had deteriorated in the month prior to death but had been stable in the 48 h prior to death and those that had deteriorated in the 48 h prior to death. Other outcomes such as the presence of chest pain or the nature of arrhythmia at the time of death were according to the investigators' opinion.
Statistical analysis
No statistical analysis of outcomes other than the primary and secondary end-points was planned prior to the study. Accordingly only a very limited number of statistical analyses are presented in this paper and these should be interpreted with appropriate caution as they were not pre-specified. However, it should be noted that the end-points in this paper are robust in that they were defined prior to breaking the study code. Log-rank tests and Cox proportional hazards regression model were applied to the individual component of the secondary outcome, severe resistant heart failure, myocardial reinfarction and stroke, and the tertiary outcome, mode of death.
Results

Morbidity
Agreement between outcome reviewers for secondary endpoints Severe resistant heart failure. Three hundred and ninetyfour episodes that could potentially be classified as an episode of severe resistant heart failure were assessed.
The reviewers independently agreed on classification, either acceptance or rejection, in 314 episodes (80%) but after consultation failed to agree in only three instances, which were therefore not validated. Three hundred and twenty-one of the 394 episodes (81%) were classified as being severe resistant heart failure. Even though 54 of the rejected 73 potential episodes of severe resistant heart failure included initiation of an ACE inhibitor, mainly for 'heart failure', because other evidence of intensive therapy directed against heart failure was lacking these were not classified as severe resistant heart failure.
Seventy-five patients reached an end-point of severe resistant heart failure prior to initial hospital discharge. Of the 246 patients who developed this endpoint subsequent to discharge, severe resistant heart failure was preceded by (25 patients) or accompanied by (19 patients) a validated myocardial reinfarction. Thus severe resistant heart failure occurred in close relation to the index myocardial infarction or to reinfarction in 37% of cases.
Myocardial infarction. Two hundred and ninety-six possible myocardial reinfarctions subsequent to randomization were reviewed; independent agreement was reached in 266 (90%), and after consultation in all 296. Myocardial reinfarction was validated (i.e. met the definition required by the end-points committee) in 171 instances (58%). Forty percent of patients (n=68) who had a recurrent myocardial infarction died vs 14% (n = 253) who did not have a recognised recurrent myocardial infarction.
Stroke. Sixty-two possible strokes were noted. Independent agreement was reached initially in 53 cases (85%) and in all cases after discussion. Forty-two strokes were validated (68%). Fig. 1) . As previously reported, ramipril reduced mortality. Progression to severe resistant heart failure was reduced (RR 23%; 95% CI 5-39%; P=0·017). There was no evidence that ramipril reduced the overall risk of reinfarction. The rate of stroke was very low and similar in both groups. 30 20 
Effects of ramipril on components of the secondary outcome (
,...
.s Figure I Event curves for overall mortality, progression to severe resistant heart failure, first-validated reinfarction and first-validated stroke. Note that the y-axis scale differs for differing outcomes. The solid line represents ramipril and the dashed line placebo. Intention-to-treat analysis. Ramipril reduced mortality by 27% (95% CI 11-40%; P=0·002). Ramipril reduced the risk of progression to severe resistant heart failure (SRHF) by 23% (95% CI 5-39%; P=0·017). Ramipril did not reduce the risk of myocardial reinfarction; risk reduction 12% (95% CI 19% increase to 35% reduction; ns). There were too few strokes to make a reliable estimate of the effect or ramipril on risk.
Deviation from randomized treatment among patients who
died. In the group randomized to placebo there were 222 deaths, 108 (49%) of which were preceded by severe resistant heart failure. Of these 108 patients, 56 received an open-label ACE inhibitor before death. Only three of the 114 patients who died without reaching a severe resistant heart failure end-point received an open-label ACE inhibitor at any time during the study. In the group randomized to ramipril there were 170 deaths, 74 (44%) of which were preceded by severe resistant heart failure. Of these 74 patients, 49 had discontinued study medication but 32 were receiving open-label ACE inhibitors and therefore only 17 were not receiving an ACE inhibitor. Of the 96 patients who died without reaching an end-point of severe resistant heart failure 23 had discontinued study medication but three were on open-label ACE inhibitors.
Hospitalization. Nine hundred and fifty-six (48%) patients were re-hospitalized at least once during the study. Ramipril reduced the number of patients re-hospitalized by 8% and the overall frequency of re-hospitalization by 10% (RR 26%; 95% CI 7-42%; P=O·Ol1). The magnitude of effect was similar to that of enalapril as observed for all-cause hospitalization in the SOL VD treatment study 13 l. Mode of death (Table 3) . Three hundred and ninetythree deaths were evaluated for mode of death. In 82% of instances the reviewers agreed independently on the mode of death and agreed on all cases after consultation.
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The end-points committee classified 210 deaths as sudden, with 143 dying due to circulatory failure and 39 dying from other causes (Table 3) . Of those dying suddenly, the final clinical course of 27 patients was deemed complicated usually with evidence of severe and worsening heart failure at the time of death. Likewise in 40 patients with established circulatory failure prior to death, and therefore appropriately classified as death due to circulatory failure, the clinical course terminated suddenly. Ramipril reduced sudden death (RR 30%; 95% CI 8-47%; P=0·011) and death due to circulatory failure (RR 18'%; 95% CI 41 to -14%) but this was only significant for sudden death (Fig. 3) . (Table 4 and Fig. 2 ). Eighty deaths occurred before initial discharge, 167 on a subsequent admission and 145 occurred out of hospital. Seven in-hospital deaths were recorded in the casualty 
Place of Death
Ramipril and mode of death 45
One hundred and thirty-seven of 247 deaths that occurred in hospital were attributed to circulatory failure, 75 to sudden death and the remainder to other causes. Of those that died in hospital a validated myocardial reinfarction had occurred within 7 days of death in 37 patients and 147 had reached the outcome severe resistant heart failure.
One hundred and thirty-five of 145 out-ofhospital deaths were attributed to sudden death, while six were attributed to circulatory failure and four to other modes. Thirty-five of these patients had reached an outcome of severe resistant heart failure and an additional 25 had worsening heart failure without validated severe resistant heart failure. Chest pain was reported in the 24 h prior to death in only 19 (13%) out-of-hospital deaths and no validated myocardial infarction had occurred within 7 days. In summary, most patients with heart failure after myocardial infarction die in hospital either on the index admission or during subsequent re-admission. The great majority of out-of-hospital deaths were recorded as sudden but 41% of out-of-hospital deaths had evidence of severe or worsening heart failure prior to death. (Figs 2 and  3 ) . Of the 210 sudden deaths 33 (16%) occurred on the first admission, and 42 (20%) on a subsequent re-admission. Out-of-hospital sudden death accounted for 135 (64%) of all sudden deaths. Of those that died suddenly after the index admission 19 had a prior validated myocardial reinfarction and in four cases this occurred within 7 days of death. Reported but unvalidated reinfarction or chest pain occurred in a further 39 patients around the time of sudden death, six during the index admission, 24 out-of-hospital and nine during re-admission. Thus evidence of myocardial ischaemia or infarction around the time of death occurred in 37 patients (21 %) dying suddenly after the index admission.
Characteristics of patients with sudden death
Fifty patients (24%) reached an end-point of severe resistant heart failure prior to sudden death and in 34 of these cases heart failure deteriorated further in the month prior to death. In a further 45 cases heart failure deteriorated in the month prior to death, of whom 17 showed further deterioration in the 48 h prior to death, but a validated end-point of severe resistant heart failure was not reached. Thus, some evidence of worsening heart failure preceded sudden death in 95 (45%) cases.
Sudden death was associated with a report of cardiac arrest in 82 cases. In 35 cases this was reported to be primarily due to ventricular tachycardia (n= 10) or fibrillation (n = 31) and 20 cases due to electromechanical dissociation, asystole or bradycardia. The rhythm was not known or not reported in 24 cases. (Figs 2 and 3) . Of the 143 deaths due to circulatory failure 43 occurred on the first admission, 94 on a subsequent admission and six out-of-hospital. Of the 100 circulatory failure deaths that occurred after the index admission, 35 (35%) had a validated myocardial reinfarction but only in 15 cases did this occur within 7 days of death. Of the 100 circulatory failure deaths occurring after the index admission, 91 had reached an end-point of severe resistant heart failure but in only 38 instances had this occurred more than one month before death. Heart failure was reported to have worsened further in the month prior to death in 94 cases (94%) and 40 of these had deteriorated further in the 48 h prior to death. Therefore as expected many patients dying of circulatory failure have evidence of worsening heart failure prior to death. However, the interval between developing severe heart failure and death often appears to be less than one month.
Characteristics of patients with death due to circulatory failure
Activity. Altogether 254 (65%) deaths occurred with the patient at rest, while the activity at the time of death was not known in 96 or not recorded in 25. Only 17 deaths were known to be related to any form of exertion, including working, eating or during toilet.
Relationship between validated severe resistant heart failure and death (Table 5 and Figs 2 and 4 ) . One hundred and forty-three patients died with validated circulatory failure; all but 17 had had previously validated severe resistant heart failure. Of the 210 sudden deaths, 50 reached an end-point of severe resistant heart failure prior to death (24%). Six patients with death due to stroke, other vascular or non-vascular modes of death had severe resistant heart failure validated prior to death. Fifty-seven percent (n = 182) of the patients who developed severe resistant heart failure subsequently died compared to 13% (n=210) of those who did not.
Relationship between worsening heart failure and death (Table 6 and Fig. 4 ) . One hundred and twenty-nine patients were considered, by their own physician, to be 'generally well' in the 24 h before death and 262 'unwell'; no data were available on one death. Only four of 80 (5%) patients who died during the index admission were considered well before death compared to 125 of 311 (40%) of those dying after initial discharge.
Thirty-six patients were considered not to have heart failure, by their physician, around the time of death, with similar numbers among those randomized to placebo and ramipril. One hundred and thirty-three were considered to have stable heart failure and 223 (57%) worsening heart failure in the month before death; 182 of these 223 patients (82%) died in hospital.
Relationship between myocardial infarction, chest pain and death (Figs 2 and 4).
Death was preceded by a validated myocardial reinfarction in 76 cases (19% of deaths), occurring within 7 days of reinfarction in 37 cases. Reported but unvalidated myocardial reinfarction occurred in a further 38 cases around the time of death. Thus, a possible or definite myocardial reinfarction occurred around the time of death in 19% of cases.
Ninety (23%) patients were recorded as having chest pain suggestive of myocardial ischaemia immediately prior to death while 165 did not and in 137 no history was available. A myocardial infarction was validated within 7 days of death in 32 of these 90 patients. ECG evidence of fresh infarction or ischaemia was recorded in 42 cases reporting chest pain prior to death, in whom an infarct was validated subsequently in 29. Seventy-one of the 90 who had chest pain recorded died in hospital and 19 out of hospital. Ramipril had no obvious effect on the frequency with which chest pain was reported among patients who subsequently died. In summary, chest pain was recorded in 23% of cases immediately prior to death, suggesting that myocardial ischaemia may have been an important factor contributing to death in these cases. However, infarction could only be validated in the minority, probably due to the rapidity of death. The contribution of myocardial ischaemia to sudden death was probably underestimated.
Other vascular events. There was strong documentary clinical evidence of pulmonary embolism contributing to death in seven cases and peripheral thrombo-embolism in 13 cases.
Cause of death-witnessed deaths.
Death was recorded as witnessed in 243 (62%) cases. Two hundred and one (83%) witnessed deaths occurred in hospital. Death attributed to circulatory failure was witnessed in 124 (87%) cases and witnessed in those thought to be due to sudden death in 97 (46%) cases. Unwitnessed deaths were classified as sudden unless circumstances suggested an alternative mode of death. Circulatory failure or a mode of death other than sudden was unwitnessed in 36 cases, the decision on defining the mode of death being made on events shortly prior to death.
Autopsy rate. Sixty-three autopsies were conducted, 52 from deaths that occurred subsequent to the initial admission. Twenty autopsies, of which 12 were >30 days after the index event suggested fresh myocardial infarction. Eleven of these 20 patients were recorded as dying suddenly. Five patients were found to have free wall myocardial rupture and one papillary muscle rupture. Five patients were discovered to have pulmonary embolism, two mesenteric infarction and three cancer. Eight patients were reported to have pulmonary oedema at post-mortem.
Arrhythmias and cardiac arrest. One hundred and thirtyone patients had an episode recorded as a cardiac arrest among those that died and 101 of these episodes occurred in patients who died in hospital. The mode of death was reported as circulatory failure, due to haemodynamic collapse prior to the arrhythmia, in 46 cases and sudden in 82 cases while three were recorded as dying of other vascular causes. Resuscitation was initially successful in 12 cases. Forty-three episodes of cardiac arrest were reported during the initial admission and 58 on subsequent admissions. The principal rhythm disturbance, in the investigators' opinions, was asystole, bradycardia or electromechanical dissociation in 64 cases and ventricular tachycardia or fibrillation in 45 cases and unknown in the remainder. Thirty out-of-hospital cardiac arrests were reported; ventricular fibrillation was identified in seven cases and electromechanical dissociation, bradycardia or asystole in 11 cases. Ramipril did not appear to reduce the proportion of deaths due to any type of arrhythmia. Forty-eight patients had an episode of supraventricular arrhythmia considered severe enough to cause haemodynamic upset prior to death. This occurred in 37 patients randomized to placebo but only 11 randomized to ramipril. Thus 26% of all deaths and 39% of sudden deaths were reported as arrhythmic. Less than half of cardiac arrests in these patients were thought to be due to a tachyarrhythmia.
Discussion
Clinical evidence of heart failure identifies a group of patients with a poor outcome after myocardial infarction, even after adjustment for the extent of ventricular dysfunction AIRE study shows a clear beneficial effect in delaying or preventing the progression of heart failure. However, the relative proportions of different modes of death were not affected by the treatment. It is hard to attribute the benefits seen with ramipril to any single mechanism of action. However, the AIRE study does provide insights into how patients with evidence of heart failure after myocardial infarction die, irrespective of the use of ACE-inhibitor therapy.
ACE Inhibitors and the mode of death
Administration of ACE inhibitors after myocardial infarction retards progressive ventricular dysfunction and delays the onset of heart failureP 5 1. However, the beneficial effects of ACE inhibitors on ventricular remodelling appear less marked than their effects on mortality[ 5 1. This suggests that ACE inhibitors could exert benefit over and above their effects purely on mechanical ventricular dysfunction. Favourable effects on potassium homeostasis, autonomic function, ventricular hypertrophy, as well as improvements in ventricular function could reduce susceptibility to arrhythmias[' 6 1. ~·The V-HeFT-II and SAVE studies both suggested that ACE inhibitors reduced the risk of sudden death with or without progressive heart failure. Indeed, the V-HeFT-II study observed no reduction in death due to progressive heart failure alone with enalapril[ 2 1. As the combination of hydralazine and nitrate also appeared to reduce, selectively, sudden death compared to placebo in V-HeFT-I it seems unlikely that the active comparator could have biased the results in favour of an effect of enalapril on arrhythmic deaths[ 17 1. The SOL VD study report is difficult to interpret as sudden death in the setting of progressive heart failure and progressive heart failure alone were not differentiated[ 3 1. All the above studies are consistent with the hypothesis that an important effect of ACE inhibitors is to prevent sudden death in the setting of worsening heart failure. The AIRE study supports this view. Reinfarction was not a prospectively determined endpoint in SOL VD while reinfarction was variously defined in SAVE, reductions achieving statistical significance using only one of three definitions. The marked reduction in mortality with ramipril in AIRE left more patients at risk of reinfarction in the ramipril treated group and the statistical correction applied may not have overcome this potentially confounding effect. Few patients were followed beyond 24 months in the AIRE study and a longer duration of follow-up, as in SAVE and SOLVD, may be necessary to demonstrate an effect. The effect of ACE inhibitors on recurrent infarction remains in doubt.
ACE inhibitors and reinfarction
Mode of death
The mode of death (e.g. sudden, circulatory) is largely a subjective assessment and should be distinguished from the objective cause of death (e.g. myocardial rupture or ventricular fibrillation) and the events around the time of death (e.g. myocardial infarction, worsening heart failure). Although the reproducibility of classification of the mode of death has been questioned, the AIRE study, using a set of objective definitions, showed a satisfactory concordance of 82% between independent assessments by two clinicians, a similar rate of agreement to that for myocardial reinfarction and stroke. Many definitions of sudden death exist. We favoured the concept of instantaneous death, choosing to include unwitnessed death in this definition unless preceded by circulatory failure or other life threatening condition such as septicaemia or cancer. Although recording unwitnessed deaths as sudden could be a source of bias, the fact that the patient is unable to call for help suggests that classification in this way is practical and valid[1 1 J. Definitions of what constitutes a death due to heart failure are few[ 111 . We chose a strict definition consistent with the concept of a situation in which the heart can no longer sustain an adequate circulation despite maximum support and where survival was unlikely without transplantation or mechanical circulatory assistance.
The mechanisms underlying sudden death remain obscure with evidence in favour variously of tachyor bradyarrhythmias[ 181 or ischaemia and infarction[l 9 • 20 l as the most important causes. That ventricular fibrillation may be a late event occurring after sudden circulatory collapse has occurred as a result of a further cardiac insult adds further complexities. Sudden death should not be equated with arrhythmic death without further supportive evidence.
The majority of patients who died in the AIRE study did so suddenly, in keeping with previous reports for the mode of death of cardiac patients overall[ 101 . Sudden death occurred in hospital in 36% of instances and out-of-hospital but with preceding severe resistant or worsening heart failure in a further 45%. Therefore up to 81% of sudden deaths are heralded by some instability of the patient's heart failure condition. Chest pain or arrhythmia were not reported frequently among those patients who died suddenly out-of-hospital but, Eur Heart J, Vol. 18 
Place of death
Unlike mode of death, place of death is highly objective and unlike cause of death, place of death can almost always be ascertained. Knowing where patients die appears informative about how patients die and could help plan strategies for management. Over one third of sudden deaths occurred in hospital and this reinforces the belief that sudden death is often predicted by some other clinical event such as worsening heart failure or myocardial reinfarction. Out-of-hospital sudden death identifies those patients who might benefit from community resuscitation programmes, though the high proportion of cardiac arrests associated with bradyarrhythmias suggests that attempts at resuscitation may not be associated with a high success rate[ 21 l. Community studies of cardiac arrest suggest that about 90% present with ventricular fibrillation[ 22 l, a much higher proportion than observed in the AIRE study. Whether this reflects a shorter time to initiation of resuscitation in community studies or a modification of the features of cardiac arrest by heart failure is uncertain, but the low proportion of ventricular fibrillation observed in hospital arrests in the AIRE study supports the latter conjecture.
Events prior to death
In the AIRE study less than 25% of patients died during symptomatic cardiac ischaemia, or if they did so they were unable to call for help. However, validated reinfarction occurred at some time in 35% of those going on to die of circulatory failure and unvalidated events occurred in a further substantial proportion. Reinfarction, in addition to remodelling, could be an important determinant of progression of heart failure.
Worsening heart failure was an almost universal accompaniment to circulatory death as would be expected, but 45% of all patients who died suddenly and 41% of those who died suddenly out-of-hospital also exhibited evidence of severe or worsening heart failure. This suggests that preventing the progression of heart failure may be effective not only in reducing overall mortality but also out-of-hospital sudden death.
Cause of death
Post-mortem evidence of the cause of death in patients with heart failure is scarce. The AIRE study highlights how infrequently the cause of death is ascertained in heart failure. The limited information available from AIRE suggest that reinfarction may be a common and under-recognized cause of death in heart failure.
Post-mortems on patients dying suddenly revealed causes as diverse as myocardial rupture and pulmonary embolism but could not, of course, determine if an arrhythmia caused sudden death.
Conclusion
After a myocardial infarction that is complicated by heart failure, even if transient, ramipril reduced mortality and the incidence of severe resistant heart failure but had no effect on reinfarction in the AIRE study. The predominant effect of ACE inhibitors on mortality appears to be mediated through a reduction of worsening heart failure, although the final mode of death is often sudden. There was no conclusive evidence to support the view that sudden death was due either to recurrent infarction or arrhythmias although recurrent infarction or arrhythmia may have been under-recognized. Altering the progression of heart failure may be the most important way in which ACE inhibitors reduce sudden death.
